Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 61Neoplasms 52Neoplasm Metastasis 48Leukemia, Myeloid, Acute 47Colorectal Neoplasms 47Breast Neoplasms 44Prostatic Neoplasms 37Multiple Myeloma 33Ovarian Neoplasms 31Recurrence 27Melanoma 26Pancreatic Neoplasms 25Lymphoma, Non-Hodgkin 25Squamous Cell Carcinoma of Head and Neck 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 22Triple Negative Breast Neoplasms 21Endometrial Neoplasms 21Lung Neoplasms 19Carcinoma, Renal Cell 19Stomach Neoplasms 18Small Cell Lung Carcinoma 18Sarcoma 18Advanced Solid Tumors 18Brain Neoplasms 17Glioblastoma 16Carcinoma, Hepatocellular 16Esophageal Neoplasms 13Solid Tumors 12Lymphoma, B-Cell 12

Interventions

tislelizumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Simpson-Golabi-Behmel syndrome × 30 days × Clear all
NCT06427941 2026-06-03

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

BeOne Medicines

Phase 1 Recruiting
392 enrolled
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡